MIRA Pharmaceuticals engages Andriy Mushak as fractional CFO

MIRA Pharmaceuticals entered into a consulting agreement with Andriy Mushak to serve as fractional chief financial officer effective June 6, 2026, providing senior financial leadership for SEC reporting, audit readiness, and capital-markets support. The engagement strengthens the company's financial infrastructure and governance capabilities as an independent contractor arrangement.